Literature DB >> 10395168

Changes in the secretion of insulin-like growth factor binding proteins -2 and -4 associated with the development of tamoxifen resistance and estrogen independence in human breast cancer cell lines.

P Maxwell1, H W van den Berg.   

Abstract

We investigated the secretion of insulin-like growth factor binding proteins (IGFBPs) by estrogen-dependent ZR-75-1 and MCF-7 human breast cancer cells, and tamoxifen-resistant (ZR-75-9a1 and LY2) and estrogen-independent (ZR-PR-LT) variants which express altered levels of IGF-I receptor. IGFBP species (35 kDa and 44 kDa) were detectable in conditioned serum-free medium (SFM) by immunoblotting and positively identified as IGFBP-2 and -3, respectively. Secretion of IGFBP-2 into SFM by the tamoxifen-resistant and estrogen-independent cell lines was markedly reduced and secretion into SFM of the 24-kDa species, assigned the identity of IGFBP-4, was also reduced in the tamoxifen-resistant lines. There was no clear correlation between patterns of IGFBP secretion and IGF-I receptor expression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10395168     DOI: 10.1016/s0304-3835(99)00009-9

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

1.  Genetic variation in IGFBP2 and IGFBP5 is associated with breast cancer in populations of African descent.

Authors:  Chad P Garner; Yuan C Ding; Esther M John; Sue A Ingles; Olufunmilayo I Olopade; Dezheng Huo; Clement Adebamowo; Temidayo Ogundiran; Susan L Neuhausen
Journal:  Hum Genet       Date:  2008-01-22       Impact factor: 4.132

2.  IGFBP-2 and -5: important regulators of normal and neoplastic mammary gland physiology.

Authors:  James Beattie; Yousef Hawsawi; Hanaa Alkharobi; Reem El-Gendy
Journal:  J Cell Commun Signal       Date:  2015-02-03       Impact factor: 5.782

3.  The dietary bioflavonoid, quercetin, selectively induces apoptosis of prostate cancer cells by down-regulating the expression of heat shock protein 90.

Authors:  Ravikumar Aalinkeel; B Bindukumar; Jessica L Reynolds; Donald E Sykes; Supriya D Mahajan; Kailash C Chadha; Stanley A Schwartz
Journal:  Prostate       Date:  2008-12-01       Impact factor: 4.104

Review 4.  Molecular markers for predicting response to tamoxifen in breast cancer patients.

Authors:  D R Ciocca; R Elledge
Journal:  Endocrine       Date:  2000-08       Impact factor: 3.925

Review 5.  IGF-Binding Protein 2 - Oncogene or Tumor Suppressor?

Authors:  Adam Pickard; Dennis J McCance
Journal:  Front Endocrinol (Lausanne)       Date:  2015-02-27       Impact factor: 5.555

6.  A candidate molecular signature associated with tamoxifen failure in primary breast cancer.

Authors:  Julie A Vendrell; Katherine E Robertson; Patrice Ravel; Susan E Bray; Agathe Bajard; Colin A Purdie; Catherine Nguyen; Sirwan M Hadad; Ivan Bieche; Sylvie Chabaud; Thomas Bachelot; Alastair M Thompson; Pascale A Cohen
Journal:  Breast Cancer Res       Date:  2008-10-17       Impact factor: 6.466

7.  Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery.

Authors:  Sharon J Pitteri; Lellean JeBailey; Vitor M Faça; Jason D Thorpe; Melissa A Silva; Reneé C Ireton; Marc B Horton; Hong Wang; Liese C Pruitt; Qing Zhang; Kuang H Cheng; Nicole Urban; Samir M Hanash; Daniela M Dinulescu
Journal:  PLoS One       Date:  2009-11-19       Impact factor: 3.240

Review 8.  Control of IGFBP-2 Expression by Steroids and Peptide Hormones in Vertebrates.

Authors:  Andreas Hoeflich; Elisa Wirthgen; Robert David; Carl Friedrich Classen; Marion Spitschak; Julia Brenmoehl
Journal:  Front Endocrinol (Lausanne)       Date:  2014-04-07       Impact factor: 5.555

9.  β-D-glucan inhibits endocrine-resistant breast cancer cell proliferation and alters gene expression.

Authors:  Zainab M T Jafaar; Lacey M Litchfield; Margarita M Ivanova; Brandie N Radde; Numan Al-Rayyan; Carolyn M Klinge
Journal:  Int J Oncol       Date:  2014-02-10       Impact factor: 5.650

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.